FDA — authorised 19 March 2014
- Application: NDA204677
- Marketing authorisation holder: LANTHEUS
- Local brand name: NEURACEQ
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
🇺🇸 Neuraceq in United States
FDA authorised Neuraceq on 19 March 2014
Marketing authorisations
FDA
- Marketing authorisation holder: LANTHEUS
- Status: approved
Neuraceq in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in United States
Frequently asked questions
Is Neuraceq approved in United States?
Yes. FDA authorised it on 19 March 2014; FDA has authorised it.
Who is the marketing authorisation holder for Neuraceq in United States?
LANTHEUS holds the US marketing authorisation.